Asthma Management Handbook

Giving bronchodilator treatment according to severity and age

Recommendations

Give initial salbutamol by inhalation, using doses, routes of administration and dosing schedules according to the patient’s age and the severity of acute asthma.

For patients with severe or life-threatening acute asthma, add ipratropium bromide.

  • Do not give oral salbultamol

Table. Rapid primary assessment of acute asthma in adults and children

Mild/Moderate

Severe

Life-threatening

Can walk, speak whole sentences in one breath

(For young children: can move around, speak in phrases)

Oxygen saturation >94%

Any of these findings:

  • Use of accessory muscles of neck or intercostal muscles or 'tracheal tug' during inspiration or subcostal recession ('abdominal breathing')
  • Unable to complete sentences in one breath due to dyspnoea
  • Obvious respiratory distress
  • Oxygen saturation 90–94%

Any of these findings:

  • Reduced consciousness or collapse
  • Exhaustion
  • Cyanosis
  • Oxygen saturation <90%
  • Poor respiratory effort, soft/absent breath sounds

Notes

If features of more than one severity category are present, record the higher (worse) category as overall severity level

The severity category may change when more information is available (e.g. pulse oximetry, spirometry) or over time.

The presence of pulsus paradoxus (systolic paradox) is not a reliable indicator of the severity of acute asthma.

Oxygen saturation measured by pulse oximetry. If oxygen therapy has already been started, it is not necessary to cease oxygen to do pulse oximetry.

Oxygen saturation levels are a guide only and are not definitive; clinical judgment should be applied.

Definitions of severity classes for acute asthma used in this handbook may differ from those used in published clinical trials and other guidelines that focus on, are or restricted to, the management of acute asthma within emergency departments or acute care facilities.

Last reviewed version 2.0

Asset ID: 74

Close

Table. Initial bronchodilator treatment in acute asthma (adults and children 6 years and over)

  • Do not use IV short-acting beta2 agonists routinely for initial bronchodilator treatment.

  • Do not give oral salbutamol.

  • Monitor for salbutamol toxicity (e.g. tachycardia, tachypnoea, metabolic acidosis, hypokalaemia) – may occur with inhaled or IV salbutamol.

Mild/Moderate

Severe

Life-threatening

Give salbutamol 4-12 puffs (100 microg/actuation) via pMDI and spacer

Give one puff at a time followed by 4 breaths

Repeat every 20-30 minutes for the first hour if required (sooner, if needed to relieve breathlessness)

Give salbutamol plus ipratropium

Salbutamol†: 12 puffs (100 microg/actuation) via pMDI and spacer

If patient unable to breathe through a spacer, give 5 mg nebule via nebuliser

Ipratropium: 8 puffs (21 microg/actuation) via pressurised metered-dose inhaler and spacer every 20 minutes for first hour. Repeat 4–6 hourly for 24 hours.

If salbutamol delivered via nebuliser add 500 micrg ipratropium to nebulised solution every 20 minutes for first hour. Repeat 4–6 hourly.

Start oxygen therapy if oxygen saturation <92% in adults or <95% in children and titrate to target:

Adults: 93–95%
Children: 95% or higher

Repeat salbutamol as needed. Give at least every 20 minutes for first hour (3 doses)

Give salbutamol plus ipratropium

Salbutamol: 2 x 5 mg nebules via continuous nebulisation driven by oxygen

Ipratropium: 500 microg ipratropium added to nebulised solution every 20 minutes for first hour. Repeat 4–6 hourly.

Maintain oxygen saturations:

Adults: 93–95%
Children: 95% or higher

Arrange immediate transfer to higher-level care

When dyspnoea improves, consider changing to salbutamol via pMDI plus spacer or intermittent nebuliser (doses as for severe acute asthma)

* Give adrenaline if anaphylaxis suspected. Consider adrenaline if the patient is unresponsive, cannot inhale bronchodilators, or is considered to be peri-arrest. 

† See Table. Using pressurised metered-dose inhalers in acute asthma

‡ See Table. Using nebulisers in acute asthma

Note: To deliver nebulised bronchodilators in a patient receiving oxygen therapy, use an air-driven compressor nebuliser and administer oxygen by nasal cannulae.

Last reviewed version 2.0

Asset ID: 80

Close

Table. Initial bronchodilator treatment in acute asthma (children 1–5 years)

  • Do not use IV short-acting beta2 agonists routinely for initial bronchodilator treatment.

  • Do not give oral salbutamol.

  • Monitor for salbutamol toxicity (e.g. tachycardia, tachypnoea, metabolic acidosis, hypokalaemia) – may occur with inhaled or IV salbutamol.

  • Closely monitor level of consciousness, fatigue, oxygen saturation, respiratory rate and heart rate. If symptoms do not respond, contact a paediatrician or senior clinician and reconsider the diagnosis. 

  • Wheezing infants younger than 12 months old should not be treated for acute asthma. Acute wheezing in this age group is most commonly due to acute viral bronchiolitis. Advice should be obtained from a paediatric respiratory physician or paediatrician before administering short-acting beta2 agonists, systemic corticosteroids or inhaled corticosteroids to an infant.

Mild/Moderate

Severe

Life-threatening*

Give salbutamol 2-6 puffs (100 microg/actuation) via pMDI and spacer plus mask

Give one puff at a time followed by 4 breaths

Repeat every 20-30 minutes for the first hour if needed (sooner, if needed to relieve breathlessness)

Give salbutamolplus ipratropium

Salbutamol: 6 puffs (100 microg/actuation) via pMDI and spacer plus mask

Give one puff at a time followed by 4 breaths

If patient unable to breathe through a spacer, give 2.5 mg nebule via nebuliser

Ipratropium: 4 puffs (21 microg/actuation) via pressurised metered-dose inhaler and spacer (+ mask if needed) every 20 minutes for first hour. Repeat 4–6 hourly for 24 hours.

If salbutamol delivered via nebuliser, add 250 microg ipratropium to nebulised solution every 20 minutes for first hour. Repeat 4–6 hourly.

Start supplementary oxygen if oxygen saturation <95%

Titrate to 95% or higher

Repeat salbutamol as needed. Give at least every 20 minutes for first hour (3 doses)

Give salbutamol plus ipratropium

Salbutamol: 2 x 2.5 mg nebules via continuous nebulisation driven by oxygen

Ipratropium: 250 microg ipratropium added to nebulised solution every 20 minutes for first hour. Repeat 4–6 hourly.

Maintain  oxygen saturation at 95% or higher

Arrange immediate transfer to higher-level care

When dyspnoea improves, consider changing to salbutamol via pMDI plus spacer or intermittent nebuliser (doses as for severe acute asthma)

*Give adrenaline if anaphylaxis suspected. Consider adrenaline if the patient is unresponsive, cannot inhale bronchodilators, or is considered to be peri-arrest.

† See Table. Using pressurised metered-dose inhalers in acute asthma

‡ See Table. Using nebulisers in acute asthma

Last reviewed version 2.0

Asset ID: 81

Close

Table. Using pressurised metered-dose inhalers in acute asthma

Administration of salbutamol by health professionals for a patient with acute asthma

  1. Use a salbutamol pressurised metered-dose inhaler (100 microg/actuation) with a spacer that has already been prepared (see note).
  2. Shake inhaler and insert upright into spacer.
  3. Place mouthpiece between the person’s teeth and ask them to seal lips firmly around mouthpiece.
  4. Fire one puff into the spacer.
  5. Tell person to take 4 breaths in and out of the spacer.
  6. Remove the spacer from mouth. Shake the inhaler after each puff before actuating again. (This can be done without detaching the pressurised metered-dose inhaler from the spacer.)

Notes

The process is repeated until the total dose is given. Different doses are recommended for patients and carers giving asthma first aid in the community.

New plastic spacers should be washed with detergent to remove electrostatic charge (and labelled), so they are ready for use when needed. In an emergency situation, if a pre-treated spacer is not available, prime the spacer before use by firing at least 10 puffs of salbutamol into the spacer. (This is an arbitrary number of actuations in the absence of evidence that would enable a precise guideline.)

Priming or washing spacers to reduce electrostatic charge before using for the first time is only necessary for standard plastic spacers. Treatment to reduce electrostatic charge is not necessary for polyurethane/antistatic polymer spacers (e.g. Able A2A, AeroChamber Plus, La Petite E-Chamber, La Grande E-Chamber) or disposable cardboard spacers (e.g. DispozABLE, LiteAire).

For small children who cannot form a tight seal with their lips around the spacer mouthpiece, attach a well-fitted mask to the spacer.

Last reviewed version 2.0

Asset ID: 62

Close

Table. Using nebulisers in acute asthma

Driving nebuliser

Nebulisers can be driven by air, piped oxygen, or an oxygen cylinder fitted with a high-flow regulator capable of delivering >6 L/min.

Salbutamol

Intermittent nebulisation with salbutamol

Use one nebule:

Adults: 5 mg nebule

Children 6 years and over: 5 mg nebule

Children aged 1-5 years: 2.5 mg nebule

Continuous nebulisation with salbutamol using nebules

Put two nebules into nebuliser chamber at a time and repeat to refill when used up.

Adults: use two 5 mg nebules (10 mg) at a time

Children 6 years and over: use two 5 mg nebules (10 mg) at a time

Children aged 1-5 years: use two 2.5 mg nebules (5 mg) at a time

Ipratropium

Add one nebule to salbutamol nebuliser solution:

Adults and children 6 years and over: 500 microg nebule

Children aged 1-5 years: 250 microg nebule

  • If using oxygen to drive a nebuliser, do not exceed 8–10 L/minute and avoid over-oxygenation (increases risk of hypercapnoea).
  • The use of nebulisers increases the risk (to staff and patients) of nosocomial aerosol infection. If using a nebuliser, follow your organisation’s infection control protocols to minimise spread of respiratory tract infections.

Last reviewed version 2.0

Asset ID: 73

Close
How this recommendation was developed

Evidence-based recommendation

Based on literature search and formulated by multidisciplinary working group.

Key evidence considered:

  • Pollock et al. 20171
  • Cates et al. 20132
  • Mitselou et al. 20163
  • Castro-Rodriguez et al. 20154
  • Kaashmiri et al. 20105
  • Chandra et al. 20056
  • Camargo et al. 20037
  • Rodrigo & Rodrigo. 20028
  • Travers et al. 20019
  • Emerman et al. 199910
  • Shrestha et al. 199611
  • Karpel et al. 199712
  • Kirkland et al. 201713
  • Pollock et al. 20171
  • Castro-Rodriguez et al. 20154
  • Vézina et al. 201415
  • Griffiths et al. 201316

Last reviewed version 2.0

For patients with severe acute asthma who are unable to breathe through a spacer, salbutamol can be given by intermittent nebulisation.

Table. Using nebulisers in acute asthma

Driving nebuliser

Nebulisers can be driven by air, piped oxygen, or an oxygen cylinder fitted with a high-flow regulator capable of delivering >6 L/min.

Salbutamol

Intermittent nebulisation with salbutamol

Use one nebule:

Adults: 5 mg nebule

Children 6 years and over: 5 mg nebule

Children aged 1-5 years: 2.5 mg nebule

Continuous nebulisation with salbutamol using nebules

Put two nebules into nebuliser chamber at a time and repeat to refill when used up.

Adults: use two 5 mg nebules (10 mg) at a time

Children 6 years and over: use two 5 mg nebules (10 mg) at a time

Children aged 1-5 years: use two 2.5 mg nebules (5 mg) at a time

Ipratropium

Add one nebule to salbutamol nebuliser solution:

Adults and children 6 years and over: 500 microg nebule

Children aged 1-5 years: 250 microg nebule

  • If using oxygen to drive a nebuliser, do not exceed 8–10 L/minute and avoid over-oxygenation (increases risk of hypercapnoea).
  • The use of nebulisers increases the risk (to staff and patients) of nosocomial aerosol infection. If using a nebuliser, follow your organisation’s infection control protocols to minimise spread of respiratory tract infections.

Last reviewed version 2.0

Asset ID: 73

Close
How this recommendation was developed

Consensus

Based on clinical experience and expert opinion after literature review yielded insufficient evidence for an evidence-based recommendation

Key evidence considered:

  • Pollock et al. 20171
  • Cates et al. 20132
  • Mitselou et al. 20163
  • Chandra et al. 20056
  • Camargo et al. 200317
  • Rodrigo & Rodrigo. 20028

Last reviewed version 2.0

For patients with life-threatening asthma, deliver salbutamol via continuous nebulisation driven by oxygen until breathing improves, then consider changing to a pressurised metered-dose inhaler plus spacer or intermittent nebuliser.

Table. Using nebulisers in acute asthma

Driving nebuliser

Nebulisers can be driven by air, piped oxygen, or an oxygen cylinder fitted with a high-flow regulator capable of delivering >6 L/min.

Salbutamol

Intermittent nebulisation with salbutamol

Use one nebule:

Adults: 5 mg nebule

Children 6 years and over: 5 mg nebule

Children aged 1-5 years: 2.5 mg nebule

Continuous nebulisation with salbutamol using nebules

Put two nebules into nebuliser chamber at a time and repeat to refill when used up.

Adults: use two 5 mg nebules (10 mg) at a time

Children 6 years and over: use two 5 mg nebules (10 mg) at a time

Children aged 1-5 years: use two 2.5 mg nebules (5 mg) at a time

Ipratropium

Add one nebule to salbutamol nebuliser solution:

Adults and children 6 years and over: 500 microg nebule

Children aged 1-5 years: 250 microg nebule

  • If using oxygen to drive a nebuliser, do not exceed 8–10 L/minute and avoid over-oxygenation (increases risk of hypercapnoea).
  • The use of nebulisers increases the risk (to staff and patients) of nosocomial aerosol infection. If using a nebuliser, follow your organisation’s infection control protocols to minimise spread of respiratory tract infections.

Last reviewed version 2.0

Asset ID: 73

Close
How this recommendation was developed

Consensus

Based on clinical experience and expert opinion after literature review yielded insufficient evidence for an evidence-based recommendation.

Key evidence considered:

  • Camargo et al. 200317
  • Rodrigo & Rodrigo. 20028
  • Shrestha et al. 199611

Last reviewed version 2.0

When using a nebuliser, follow your organisation’s infection control protocols to minimise spread of respiratory tract infections.

How this recommendation was developed

Consensus

Based on clinical experience and expert opinion (informed by evidence, where available).

Last reviewed version 2.0

To deliver intermittent nebulised bronchodilators in a patient receiving oxygen therapy, use an air-driven compressor nebuliser and administer oxygen by nasal cannulae.

Titrate oxygen to target SpO2 93–95% in adults or at least 95% in children.

If nebulised salbutamol is needed for a patient receiving supplemental oxygen, the nebuliser can be driven by piped (‘wall’) oxygen or an oxygen cylinder fitted with a high-flow regulator capable of delivering >6 L/min. The patient should be changed back to their original oxygen mask once nebulisation is complete.

  • In adults, avoid over-oxygenation (SpO2>95%), because this increases the risk of hypercapnoea.
How this recommendation was developed

Consensus

Based on clinical experience and expert opinion (informed by evidence, where available), with particular reference to named source(s):

  • Beasley et al. 201518

Last reviewed version 2.0

If non-invasive ventilation has been initiated, salbutamol can be delivered using any of the following options:

  • Briefly interrupt ventilation to deliver salbutamol via pressurised metered-dose inhaler and spacer.
  • Deliver inline via pressurised metered-dose inhaler.

Attach nebuliser to the ventilator circuit with the expiration port between the facemask and nebuliser.

  • Do not sedate patient
  • If no improvement, intubate and start mechanical ventilation

Note: Non-invasive positive pressure ventilation can be considered if patient is starting to tire, or develops type 2 respiratory failure. Mechanical ventilation should be used for patients with respiratory arrest, acute respiratory failure that does not respond to treatment, or failure to respond to noninvasive positive pressure ventilation.

How this recommendation was developed

Consensus

Based on clinical experience and expert opinion (informed by evidence, where available), with particular reference to named source(s):

  • Calvert et al. 200619

Last reviewed version 2.0

Do not give oral salbutamol.

How this recommendation was developed

Consensus

Based on clinical experience and expert opinion (informed by evidence, where available), with particular reference to named source(s):

  • Graig et al. 201620
  • Herd 201121

Last reviewed version 2.0

Do not routinely use IV short-acting beta2 agonists.

Note: IV salbutamol can be considered in critical care units for patients with life-threatening acute asthma that has not responded to continuous nebulised salbutamol, after considering other add-on treatment options.

How this recommendation was developed

Evidence-based recommendation

Based on literature search and formulated by multidisciplinary working group.

Key evidence considered:

  • Travers et al. 201222
  • Travers et al. 201223
  • Travers et al. 20019
  • Bogie et al. 200724

Last reviewed version 2.0

More information

Salbutamol in acute asthma

Route of administration

Inhaler plus spacer, or nebuliser

Among patients with acute asthma who do not require mechanical ventilation, salbutamol delivered via a pressurised metered-dose inhaler with spacer is at least as effective as salbutamol delivered via nebuliser in preschool children (with viral-induced wheezing or acute asthma)3 and adults,2526 and is equivalent or superior in school-aged children.4, 2, 1, [REFERENCE991]

The use of nebulisers increases the risk of transmitting respiratory infections to staff and other patients,27 and increases the risk of adverse effects.

Intravenous salbutamol

IV salbutamol is generally reserved for use in patients with severe acute asthma that does not respond to inhaled bronchodilators.

Efficacy

Overall, intravenous short-acting beta2 agonists do not appear to be superior to inhaled short-acting beta2 agonist.28

Adults

Benefits have not been demonstrated in adults.28 

Children

Very limited evidence from one study suggested that the addition of IV salbutamol to inhaled salbutamol reduced recovery time in children with severe acute asthma in the emergency department.28

However, there is a lack of consensus on the appropriate dose of IV salbutamol for children.29 Recommendations differ between guidelines in Australia30 and elsewhere.29 Doses have not been calculated based on age-specific pharmacokinetic and pharmacodynamic data. The doses recommended in guidelines are generally relatively higher than for adults on a micrograms per kilogram body weight basis.

Adverse effects

Compared with inhaled salbutamol, intravenous salbutamol is associated with increased risk of adverse effects including tremor and hypokalaemia.2829  Concomitant use of the inhalation and IV routes may increase the risk of salbutamol toxicity.31

Note: Salbutamol concentrate for infusion is available in 5 mL ampoules containing salbutamol sulfate equivalent to 5 mg (1 mg/mL) salbutamol in a sterile isotonic solution (Ventolin obstetric injection). Salbutamol for injection is also available in ampoules of salbutamol sulphate equivalent to 500 microg salbutamol in 1 mL sterile isotonic solution (Ventolin injection).

Salbutamol dosing regimens

There is very little evidence from clinical trials to guide dosing intervals for salbutamol treatment in acute asthma.

One placebo-controlled study conducted in the emergency department among adults with acute asthma (FEV1 <60% predicted or normal) showed that, in those who did not show a clear response to the first salbutamol dose, repeating the dose at intervals of 30 minutes or less was more effective than every 60 minutes.12 However, for patients who showed clear improvement after the first dose of salbutamol via pressurised metered-dose inhaler and spacer, there was no advantage in repeating the dose more often than every 60 minutes until full recovery (extra doses can be given as needed).12

Last reviewed version 2.0

Close
Ipratropium in acute asthma

Adults

In adults and older adolescents with severe acute asthma treated in the emergency department, the combination of ipratropium and short-acting beta2 agonist reduces hospitalisation rate and improves lung function, compared with short-acting beta2 agonist alone.13 Hospitalisation rates are not reduced in patients with mild or moderate acute asthma.13

In adults, the combination of ipratropium and short-acting beta2 agonist is associated with a higher rate of adverse effects (e.g. tremor, agitation, and palpitations) than short-acting beta2 agonist alone.13

Children

Recent systematic reviews have reported that initial treatment with ipratropium in addition to salbutamol markedly reduces hospitalisation rate and improves clinical scores in children with moderate to severe acute asthma.4, 1, 16

However, in children hospitalised due to acute asthma, the combination of ipratropium and short-acting beta2 agonist was not more effective than short-acting beta2 agonist alone.15

The combination of ipratropium and short-acting beta2 agonist appears to be well tolerated in children.16

Ipratropium bromide alone is less effective than salbutamol alone in acute asthma.32

Last reviewed version 2.0

Close
Oxygen therapy in acute asthma

Oxygen is a treatment for hypoxaemia, not breathlessness.18 Oxygen has not been shown to improve the sensation of breathlessness in non-hypoxaemic patients.18 When oxygen supplementation is used, pulse oximetry is necessary to monitor oxygen status and titrate to target.

The aim of titrated oxygen therapy in acute care is to achieve adequate oxygen saturation without causing hypercapnoea.18 Adults with acute asthma and those with overlapping asthma and COPD are at greater risk of hypercapnoeic respiratory failure.

Drying of the upper airway is a potential complication of oxygen therapy,33, 34 and might contribute to bronchoconstriction.34

Few studies have investigated optimal oxygen supplementation protocols for patients with asthma.

Adults

In adults with acute asthma, titrated oxygen therapy using pulse oximetry to maintain oxygen saturation at 93–95% while avoiding hyperoxaemia achieves better physiological outcomes than 100% oxygen at high flow rate (8 L/min).35 High-concentration and high-flow oxygen therapy cause a clinically significant increase in blood CO2 concentration in adults with acute asthma.35, 36

Thoracic Society of Australia and New Zealand (TSANZ) clinical practice guidelines for acute oxygen use in adults18 recommend that, in patients with COPD, oxygen should be administered if the SpO2 is less than 88%, and titrated to a target SpO2 range of 88–92%. For other acute medical conditions, the TSANZ guidelines recommend that oxygen should be administered if the SpO2 is less than 92%, and titrated to a target SpO2 range of 92–96%.

Humidification of oxygen via high flow nasal cannulae may improve comfort and tolerance.18

Children

There is very little evidence available to inform recommendations for oxygen saturation targets in children with asthma.37 Studies in infants with bronchiolitis suggest that targets as low as >90%38 or >92%39 may be achieve similar clinical outcomes as higher targets. Recommendations for oxygen saturation targets during supplemental oxygen vary between clinical guidelines and vary between protocols used in Australian hospitals.

Humidified oxygen can be considered if necessary. Humidification is usually not needed for low flow oxygen (<4 L/minute in children or 2 L/minute in infants) for short term. Humidification may be considered if the oxygen is required for longer than 48 hours or if the nasal passages are becoming uncomfortable or dry.33

Guidance on oxygen delivery techniques and practical issues is available from Sydney Children's Hospital Network and The Royal Children's Hospital Melbourne.

Humidified oxygen via high-flow nasal cannulae

Humidified high flow nasal oxygen is a system that has the ability to provide a humidified high-flow mix of air and oxygen via a specialised nasal cannula system. It is able to deliver positive end expiratory pressure of approximately 4–8 cm H20.

Delivery of high-flow oxygen via nasal cannulae is increasingly common practice in Australian emergency rooms. There is very little evidence to support its use in acute asthma treatment,18 but it does not appear to be associated with significant risks.

It has been reported to be feasible and safe in children with severe acute asthma in ICU,40 and at least as effective as conventional oxygen therapy in children with acute asthma with inadequate response to initial bronchodilator treatment.40 No published studies have evaluated its use in adults with acute asthma.

Last reviewed version 2.0

Close
Heliox in acute asthma

The rationale for its use of heliox (mixture of helium and oxygen in various proportions) in patients with asthma is that the low density may improve airflow in the presence of turbulence within the airways.41 It has negligible adverse effects.41

When giving nebulised bronchodilators in acute asthma, the use of heliox to drive the nebuliser may be more effective than oxygen for improving lung function and reducing hospital admission rates in adults and children.42, 4 However, overall evidence for benefits in the treatment of children with acute asthma is inconclusive.41

Heliox may not have any benefit for patients with severe asthma requiring mechanical ventilation.43

Heliox is not commonly used in Australian emergency departments and is not routinely available.

Last reviewed version 2.0

Close
Technical notes: pressurised metered-dose inhalers with spacers

Manufacturers of most pressurised metered-dose delivery devices recommend shaking the device before actuating. The physical characteristics of each formulation, including the effects of shaking, differ widely,44 but for simplicity it is best always to recommend shaking of pressurised metered-dose inhalers.

Pressurised metered-dose inhalers (except for those that are breath-actuated) can be used with a spacer. When a spacer is used with a pressurised metered-dose inhaler, delivery of the medicine to the patient’s airways is maximised when the patient takes a slow, deep breath from the spacer after each actuation.4536 Multiple actuations of a pressurised metered-dose inhaler into a spacer can reduce the amount of respirable medicine available because aerosol particles can agglomerate into larger particles or become attached to the spacer walls.45

Therefore, the ideal way to deliver inhaled medicines via pressurised metered-dose inhaler and spacer is to shake the device, ask the person to breathe out all the way into the spacer, actuate a single puff into the spacer, and have the person immediately take a slow deep breath from the spacer, then hold their breath for 5 seconds. This process should be repeated until the total intended number of actuations is taken. Patients should be trained to follow these instructions when using their inhalers. Inhaling slowly with a single breath maximises delivery of the medicine to the lungs and minimises deposition in the upper airways when using a manually actuated pressurised metered-dose inhaler with or without a spacer, or when using a breath-actuated pressurised metered-dose inhaler.46 However, slow breathing may not be possible for patients with acute asthma. Tidal breathing through the spacer (e.g. four breaths in and out without removing the spacer) is used in acute asthma and for very young children. First aid instructions should include how to use inhaler and spacer.

In practice, optimal delivery of inhaled medicines involves a balance between maximising the proportion of respirable medicine and maximising efficiency of inhalation by the patient within real-world constraints. The optimal delivery of salbutamol in real-world circumstances is not well defined. For day-to-day use of salbutamol, most adults gain sufficient relief from symptoms when using a pressurised metered-dose inhaler on its own. A spacer may only be needed during a flare-up. By contrast, the use of a spacer is always recommended for inhaled corticosteroids delivered by manually actuated pressurised metered-dose inhalers, to reduce the risk of local adverse effects and increase delivery to the airways.

Many available in vitro studies of aerosol particle deposition in the airways were performed using older CFC-propelled formulations, which are now obsolete. Similar studies have not been performed for current non-CFC pressurised metered-dose inhalers.

Last reviewed version 2.0

Close

References

  1. Pollock M, Sinha IP, Hartling L et al. Inhaled short-acting bronchodilators for managing emergency childhood asthma: an overview of reviews. Allergy. 2017; 72: 183-200. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27588581
  2. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2013; 9: Cd000052. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24037768
  3. Mitselou N, Hedlin G, Hederos CA. Spacers versus nebulizers in treatment of acute asthma - a prospective randomized study in preschool children. J Asthma. 2016; 53: 1059-62. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27186989
  4. Castro-Rodriguez, J. A., Rodrigo, G. J., Rodriguez-Martinez, C. E.. Principal findings of systematic reviews for chronic treatment in childhood asthma. J Asthma. 2015; 52: 1038-45. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26303207
  5. Kaashmiri, M, Shepard, J, Goodman, B, et al. Repeat dosing of albuterol via metered-dose inhaler in infants with acute obstructive airway disease: a randomized controlled safety trial. Pediatr Emerg Care. 2010; 26: 197-202. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20179658
  6. Chandra, A, Shim, C, Cohen, H W, et al. Regular vs ad-lib albuterol for patients hospitalized with acute asthma. Chest. 2005; 128: 1115-1120. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16162695
  7. Camargo CA, Spooner C, Rowe BH. Continuous versus intermittent beta-agonists for acute asthma. Cochrane Database Syst Rev. 2003; Issue 4: CD001115. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001115/full
  8. Rodrigo, G J, Rodrigo, C. Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest. 2002; 122: 160-165. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12114352
  9. Travers, A A, Jones, A P, Kelly, K D, et al. Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database Syst Rev. 2001; Issue 1: CD002988. Available from: http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD002988/full
  10. Emerman, C L, Cydulka, R K, McFadden, E R. Comparison of 2.5 vs 7.5 mg of inhaled albuterol in the treatment of acute asthma. Chest. 1999; 115: 92-96. Available from: https://www.ncbi.nlm.nih.gov/pubmed/9925067
  11. Shrestha, M, Bidadi, K, Gourlay, S, Hayes, J. Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults. Chest. 1996; 110: 42-47. Available from: https://www.ncbi.nlm.nih.gov/pubmed/8681661
  12. Karpel JP, Aldrich TK, Prezant DJ, et al. Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered?. Chest. 1997; 112: 348-356. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9266868
  13. Kirkland SW, Vandenberghe C, Voaklander B et al. Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma. Cochrane Database Syst Rev. 2017; Issue 1: CD001284. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28076656
  14. Capsomidis, A., Tighe, M.. Archimedes. Question 2. Is oral montelukast beneficial in treating acute asthma exacerbations in children?. Arch Dis Child. 2010; 95: 948-50. Available from: http://adc.bmj.com/content/95/11/948.long
  15. Vezina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital.Cochrane Database Syst Rev. 2014; Issue 7: CD010283. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25080126/
  16. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2013: Cd000060. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23966133
  17. Camargo, C A, Spooner, Catherine, Rowe, B H. Continuous versus intermittent beta-agonists for acute asthma. Cochrane Database Syst Rev. 2003; Issue 4: . Available from: https://www.ncbi.nlm.nih.gov/pubmed/14583926
  18. Beasley R, Chien J, Douglas J et al. Thoracic Society of Australia and New Zealand oxygen guidelines for acute oxygen use in adults: ‘Swimming between the flags". Respirology. 2015; 20: 1182–91. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26486092/
  19. Calvert, L D, Jackson, J M, White, J A, et al. Enhanced delivery of nebulised salbutamol during non-invasive ventilation. J Pharm Pharmacol. 2006; 58: 1553-1557. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17132219
  20. Craig, S, Tuszynski, M, Armstrong, D. It is time to stop prescribing oral salbutamol. Aust Prescr. 2016; 45: 245-247. Available from: https://www.racgp.org.au/afp/2016/april/it-is-time-to-stop-prescribing-oral-salbutamol/
  21. Herd D. Oral versus inhaled salbutamol for acute paediatric asthma. Best Bets [serial on the Internet]. 2011: Available from: https://bestbets.org/bets/bet.php?id=2283/
  22. Travers, A H, Milan, S J, Jones, A P, et al. Addition of intravenous beta. Cochrane Database Syst Rev. 2012; Issue 12: CD010179. Available from: http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD010179/full
  23. Travers AH, Jones AP, Camargo CA et al. Intravenous beta2-agonists versus intravenous aminophylline for acute asthma. Cochrane Database Syst Rev 2012; Issue 12: CD010256. Available from:https://www.ncbi.nlm.nih.gov/pubmed/23235686/
  24. Bogie, A L, Towne, D, Luckett, P M, et al. Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. Pediatr Emerg Care. 2007; 23: 355-361. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17572517
  25. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2006; Issue 2: CD000052. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000052.pub2/full
  26. Dhuper S, Chandra A, Ahmed A, et al. Efficacy and cost comparisons of bronchodilatator administration between metered dose inhalers with disposable spacers and nebulizers for acute asthma treatment. J Emerg Med. 2011; 40: 247-55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19081697
  27. Tran K, Cimon K, Severn M et al. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One. 2012; 7: e35797. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22563403
  28. Travers AH, Milan SJ, Jones AP, et al. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. Cochrane Database Syst Rev. 2012; 12: CD010179. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010179/full
  29. Starkey ES, Mulla H, Sammons HM, Pandya HC. Intravenous salbutamol for childhood asthma: evidence-based medicine?. Arch Dis Child. 2014; 99: 873-877. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24938536
  30. Babl FE, Sheriff N, Borland M, et al. Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines. Arch Dis Child. 2008; 93: 307-312. Available from: http://adc.bmj.com/content/93/4/307.abstract
  31. Abramson MJ, Bailey MJ, Couper FJ, et al. Are asthma medications and management related to deaths from asthma?. Am J Respir Crit Care Med. 2001; 163: 12-18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11208619
  32. Teoh L, Cates CJ, Hurwitz M, et al. Anticholinergic therapy for acute asthma in children. Cochrane Database Syst Rev. 2012; 4: CD003797. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003797.pub2/full
  33. Sydney Children's Hospital. Oxygen therapy and delivery devices – SCH. Practice guideline. Guideline No: 0/C/13:7019-01:00. Sydney Children's Hospital Westmead, Sydney, 2013. Available from: http://www.chw.edu.au/about/policies/alphabetical.htm
  34. The Royal Children's Hospital of Melbourne, Oxygen Delivery. Clinical Guidelines (Nursing), The Royal Children's Hospital 2013. Available from: http://www.rch.org.au/rchcpg/hospitalclinicalguidelineindex/Oxygendelivery/
  35. Perrin K, Wijesinghe M, Healy B, et al. Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax. 2011; 66: 937-41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21597111
  36. Rau JL, Restrepo RD, Deshpande V. Inhalation of single vs multiple metered-dose bronchodilator actuations from reservoir devices : An in vitro study. Chest. 1996; 109: 969-974. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8635379
  37. Tosif S, Duke T. Evidence to support oxygen guidelines for children with emergency signs in developing countries: a systematic review and physiological and mechanistic analysis. J Trop Pediatr. 2017; 63: 402-13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28158795
  38. Cunningham S, Rodriguez A, Adams T et al. Oxygen saturation targets in infants with bronchiolitis (BIDS): a double-blind, randomised, equivalence trial. Lancet. 2015; 386: 1041-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26382998
  39. Franklin D, Babl FE, Schlapbach LJ et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. N Engl J Med. 2018; 378: 1121-31. Available from:https://www.ncbi.nlm.nih.gov/pubmed/29562151/
  40. Ballestero Y, De Pedro J, Portillo N et al. Pilot clinical trial of high-flow oxygen therapy in children with asthma in the emergency service. J Pediatr. 2018; 194: 204-10.e3. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29331328/
  41. Rehder KJ. Adjunct therapies for refractory status asthmaticus in children. Respir Care 2017; 62: 849-65. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28546381/
  42. Rodrigo GJ, Castro-Rodriguez JA. Heliox-driven beta2-agonists nebulization for children and adults with acute asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2014; 112: 29-34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24331390
  43. Leatherman JW, Romero RS, Shapiro RS. Lack of benefit of Heliox during mechanical ventilation of subjects with severe air-flow obstruction. Respir Care. 2018; 63: 375-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29279363
  44. Cyr TD, Graham SJ, Li KY, Levering EG. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res. 1991; 8: 658-660. Available from: http://link.springer.com/article/10.1023/A:1015825311750
  45. Barry PW, O'Callaghan C. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range. Eur Respir J. 1994; 7: 1707-1709. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7995401
  46. Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011; 37: 1308-1417. Available from: http://erj.ersjournals.com/content/37/6/1308.full